A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma

Abstract

Our 36-gene classifier is able to prognosticate PDAC independent of patient cohort and microarray platforms. Further work on the functional roles, downstream events and interactions of the signature genes is likely to reveal true molecular candidates for PDAC therapeutics.